GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Documenti analoghi

• Prognostic Accuracy of the SIRS, qSOFA, and NEWS for Early Detection of Clinical Deterioration in SARS-CoV-2 Infected Patients
  di: Jang, Jong Geol, et al.
  Pubblicazione: (2020)
• Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm
  di: Lee, Yun Young, et al.
  Pubblicazione: (2021)
• Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
  di: Hong, Kyung Soo, et al.
  Pubblicazione: (2020)
• COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm
  di: Lee, Wonhwa, et al.
  Pubblicazione: (2020)
• Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
  di: Hong, Kyung Soo, et al.
  Pubblicazione: (2020)